ArticleJournal of virology2025
Impact of the changes in substrate specificity of herpes simplex virus 1 protein kinase Us3 on viral infection
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identification of UL3.5 as a novel substrate of DPV US3 kinase whose phosphorylation at Ser64/Ser84 enhances protein stability and promotes viral release, and cell-to-cell spread.Poultry science · 2026Article
- Evolution-guided prioritization identifies a tissue-specific phosphorylation switch on herpes simplex virus 1 UL7 regulating viral replication and pathogenicity.Journal of virology · 2026Article
- HSV-1 US3: A Master Mimic Hijacking Host Kinase Networks for Viral Dominance.Journal of medical virology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A serine-threonine protein kinase (PK), Us3, encoded by herpes simplex virus 1 (HSV-1), shares substrate specificity with host cellular PKs, protein kinase A (PKA), and AKT. Many Us3 substrates have been identified, and it is thought that during HSV-1 infection, Us3 fine-tunes the phosphorylation levels of individual substrates within their repertoire. However, the significance of this regulatory fine-tuning by Us3 during HSV-1 infection is poorly understood. Here, we found alanine at position 326 (Ala-326) in Us3 was required for the proper fine-tuning of Us3-mediated phosphorylation across the target repertoire in HSV-1-infected cells. Using recombinant viruses in which Us3 Ala-326 was replaced with valine (A326V) or isoleucine (A326I), we showed these mutations selectively altered the phosphorylation of only a subset of at least 14 Us3 target proteins tested in HSV-1-infected cells, with each mutation generally affecting different targets. Of note, (i) both mutations significantly reduced plaque sizes without affecting viral replication in cell cultures; (ii) the Us3 A326I mutation impaired viral replication in the brains of mice and improved survival following intracranial infection, whereas the Us3 A326V mutation had little effect; and (iii) the Us3 A326V mutation reduced ocular pathogenic manifestations and viral replication in the trigeminal ganglia and brains of mice, thereby improving survival following ocular infection. Taken together, these results suggest that the proper fine-tuning of Us3-mediated phosphorylation across its target repertoire is required for efficient cell-to-cell spread of HSV-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.